Alaunos Therapeutics (TCRT) Stock Price, News & Analysis

Company Overview

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

Key Stats

• Today's Range: $2.41 to $2.50
• 50-Day Range: $1.77 to $4.00
• 52-Week Range: $1.31 to $6.20
• Volume: 18,693 shs
• Average Volume: 337,296 shs
• Market Capitalization: $5.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Alaunos Therapeutics Stock Analysis - MarketRank™

Alaunos Therapeutics scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Alaunos Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Alaunos Therapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alaunos Therapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alaunos Therapeutics has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.40% of the float of Alaunos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Alaunos Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alaunos Therapeutics has recently increased by 730.58%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alaunos Therapeutics does not currently pay a dividend.

Dividend Growth

Alaunos Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.40% of the float of Alaunos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Alaunos Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alaunos Therapeutics has recently increased by 730.58%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for TCRT on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Alaunos Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alaunos Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.14% of the stock of Alaunos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 27.72% of the stock of Alaunos Therapeutics is held by institutions.

TCRT Stock Analysis - Frequently Asked Questions

How have TCRT shares performed this year?

Alaunos Therapeutics' stock was trading at $1.90 on January 1st, 2025. Since then, TCRT shares have increased by 27.4% and is now trading at $2.42.

How were Alaunos Therapeutics' earnings last quarter?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) announced its quarterly earnings data on Thursday, August, 14th. The company reported ($0.63) EPS for the quarter, topping analysts' consensus estimates of ($5.33) by $4.70.

When did Alaunos Therapeutics' stock split?

Alaunos Therapeutics's stock reverse split on Thursday, July 18th 2024.The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Alaunos Therapeutics?

Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alaunos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alaunos Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), American Water Works (AWK) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/20/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TCRT
• CIK: 1107421
• Web: www.alaunos.com
• Phone: (346) 355-4099
• Fax: 617-241-2855
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.68 million
• Net Margins: N/A
• Pretax Margin: -66,533.33%
• Return on Equity: -168.02%
• Return on Assets: -121.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.48
• Quick Ratio: 3.48

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 534.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.29 per share
• Price / Book: 1.88

Miscellaneous

• Outstanding Shares: 2,210,000
• Free Float: 1,850,000
• Market Cap: $5.35 million
• Optionable: No Data
• Beta: -0.82